{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T02:51:26Z","timestamp":1767927086214,"version":"3.49.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Amyotrophic lateral sclerosis (ALS), a progressive and fatal neurodegenerative disorder, primarily affects the motor neurons of the brain and spinal cord. Like other neurodegenerative conditions, ongoing pathological processes such as increased inflammation, excitotoxicity, and protein accumulation contribute to neuronal death. Hepatocyte growth factor (HGF) signaling through the MET receptor promotes pro-survival, anti-apoptotic, and anti-inflammatory effects in multiple cell types, including the neurons and support cells of the nervous system. This pleiotropic system is therefore a potential therapeutic target for treatment of neurodegenerative disorders such as ALS. Here, we test the effects of ATH-1105, a small-molecule positive modulator of the HGF signaling system, in preclinical models of ALS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:italic>In vitro<\/jats:italic>, the impact of ATH-1105 on HGF-mediated signaling was assessed via phosphorylation assays for MET, extracellular signal\u2013regulated kinase (ERK), and protein kinase B (AKT). Neuroprotective effects of ATH-1105 were evaluated in rat primary neuron models including spinal motor neurons, motor neuron-astrocyte cocultures, and motor neuron-human muscle cocultures. The anti-inflammatory effects of ATH-1105 were evaluated in microglia- and macrophage-like cell systems exposed to lipopolysaccharide (LPS). <jats:italic>In vivo<\/jats:italic>, the impact of daily oral treatment with ATH-1105 was evaluated in Prp-TDP43<jats:sup>A315T<\/jats:sup> hemizygous transgenic ALS mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>In vitro<\/jats:italic>, ATH-1105 augmented phosphorylation of MET, ERK, and AKT. ATH-1105 attenuated glutamate-mediated excitotoxicity in primary motor neurons and motor neuron- astrocyte cocultures, and had protective effects on motor neurons and neuromuscular junctions in motor neuron-muscle cocultures. ATH-1105 mitigated LPS-induced inflammation in microglia- and macrophage-like cell systems. <jats:italic>In vivo<\/jats:italic>, ATH-1105 treatment resulted in improved motor and nerve function, sciatic nerve axon and myelin integrity, and survival in ALS mice. Treatment with ATH-1105 also led to reductions in levels of plasma biomarkers of inflammation and neurodegeneration, along with decreased pathological protein accumulation (phospho-TDP-43) in the sciatic nerve. Additionally, both early intervention (treatment initiation at 1 month of age) and delayed intervention (treatment initiation at 2 months of age) with ATH-1105 produced benefits in this preclinical model of ALS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The consistent neuroprotective and anti-inflammatory effects demonstrated by ATH-1105 preclinically provide a compelling rationale for therapeutic interventions that leverage the positive modulation of the HGF pathway as a treatment for ALS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnins.2024.1348157","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T05:10:05Z","timestamp":1707369005000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS"],"prefix":"10.3389","volume":"18","author":[{"given":"Andr\u00e9e-Anne","family":"Berthiaume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif M.","family":"Reda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla N.","family":"Kleist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharay E.","family":"Setti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jewel L.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liana R.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J.","family":"Moebius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin J.","family":"Church","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s11064-007-9564-x","article-title":"Elevated inflammatory markers in a group of amyotrophic lateral sclerosis patients from northern India","volume":"33","author":"Babu","year":"2008","journal-title":"Neurochem. Res."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"14266","DOI":"10.1038\/s41598-017-14399-5","article-title":"Disulfide cross-linked multimers of tdp-43 and spinal motoneuron loss in a tdp-43(a315t) ALS\/FTD mouse model","volume":"7","author":"Bargsted","year":"2017","journal-title":"Sci. Rep."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e1466","DOI":"10.1212\/WNL.0000000000012632","article-title":"Prediagnostic neurofilament light chain levels in amyotrophic lateral sclerosis","volume":"97","author":"Bjornevik","year":"2021","journal-title":"Neurology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.2174\/0929867321666140916120118","article-title":"The glutamate hypothesis in als: pathophysiology and drug development","volume":"21","author":"Blasco","year":"2014","journal-title":"Curr. Med. Chem."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1002\/jnr.24714","article-title":"Combination of acamprosate and baclofen (pxt864) as a potential new therapy for amyotrophic lateral sclerosis","volume":"98","author":"Boussicault","year":"2020","journal-title":"J. Neurosci. Res."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1093\/hmg\/ddw161","article-title":"Disruption of the astrocytic tnfr1-gdnf axis accelerates motor neuron degeneration and disease progression in amyotrophic lateral sclerosis","volume":"25","author":"Brambilla","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/0022-510X(95)00315-S","article-title":"Neurotrophins increase motoneurons' ability to innervate skeletal muscle fibers in rat spinal cord--human muscle cocultures","volume":"136","author":"Braun","year":"1996","journal-title":"J. Neurol. Sci."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e0160520","DOI":"10.1371\/journal.pone.0160520","article-title":"RNAseq analyses identify tumor necrosis factor-mediated inflammation as a major abnormality in ALS spinal cord","volume":"11","author":"Brohawn","year":"2016","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Brown","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00401-022-02436-1","article-title":"Increased nf-l levels in the tdp-43(g298s) ALS mouse model resemble nf-l levels in als patients","volume":"144","author":"Buck","year":"2022","journal-title":"Acta Neuropathol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.adgen.2015.07.001","article-title":"Functional significance of tdp-43 mutations in disease","volume":"91","author":"Buratti","year":"2015","journal-title":"Adv. Genet."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2741\/2727","article-title":"Multiple roles of tdp-43 in gene expression, splicing regulation, and human disease","volume":"13","author":"Buratti","year":"2008","journal-title":"Front. Biosci."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0022-510X(94)90185-6","article-title":"Rapid purification of embryonic rat motoneurons: an in vitro model for studying MND\/ALS pathogenesis","volume":"124","author":"Camu","year":"1994","journal-title":"J. Neurol. Sci."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.3390\/ijms18102092","article-title":"Neuromuscular junction dismantling in amyotrophic lateral sclerosis","volume":"18","author":"Cappello","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neurobiolaging.2016.09.016","article-title":"Characterizing axonal myelination within the healthy population: a tract-by-tract mapping of effects of age and gender on the fiber g-ratio","volume":"49","author":"Cercignani","year":"2017","journal-title":"Neurobiol. Aging"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"117070","DOI":"10.1016\/j.jns.2020.117070","article-title":"Exosomal tar DNA-binding protein-43 and neurofilaments in plasma of amyotrophic lateral sclerosis patients: a longitudinal follow-up study","volume":"418","author":"Chen","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"e7754","DOI":"10.1371\/journal.pone.0007754","article-title":"What is the optimal value of the g-ratio for myelinated fibers in the rat CNS? A theoretical approach","volume":"4","author":"Chomiak","year":"2009","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.molmed.2011.06.004","article-title":"Tdp-43 functions and pathogenic mechanisms implicated in tdp-43 proteinopathies","volume":"17","author":"Cohen","year":"2011","journal-title":"Trends Mol. Med."},{"key":"ref19","volume-title":"Amx0035 for the treatment of amyotrophic lateral sclerosis (ALS)","year":"2022"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1517\/14728222.11.11.1415","article-title":"Glutamate excitotoxicity and therapeutic targets for amyotrophic lateral sclerosis","volume":"11","author":"Corona","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/glia.23728","article-title":"The microglial nlrp3 inflammasome is activated by amyotrophic lateral sclerosis proteins","volume":"68","author":"Deora","year":"2020","journal-title":"Glia"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"683609","DOI":"10.3389\/fcell.2021.683609","article-title":"Hgf and met: from brain development to neurological disorders","volume":"9","author":"Desole","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1002\/dneu.22382","article-title":"Distinct intracellular signaling mediates c-met regulation of dendritic growth and synaptogenesis","volume":"76","author":"Eagleson","year":"2016","journal-title":"Dev. Neurobiol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1089\/ars.2009.2444","article-title":"Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis","volume":"11","author":"Foran","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jocn.2012.11.007","article-title":"An immunohistochemical study of increased tumor necrosis factor-\u03b1 in the skin of patients with amyotrophic lateral sclerosis","volume":"20","author":"Fukazawa","year":"2013","journal-title":"J. Clin. Neurosci."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4152","DOI":"10.3390\/ijms20174152","article-title":"Diagnostic and prognostic role of blood and cerebrospinal fluid and blood neurofilaments in amyotrophic lateral sclerosis: a review of the literature","volume":"20","author":"Gagliardi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1001\/jamaneurol.2016.5398","article-title":"Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease","volume":"74","author":"Gaiani","year":"2017","journal-title":"JAMA Neurol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-60761-756-3_1","article-title":"Protein misfolding and cellular stress: an overview","volume":"648","author":"Gregersen","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.3390\/cells10030518","article-title":"Tumor necrosis factor alpha in amyotrophic lateral sclerosis: friend or foe?","volume":"10","author":"Guidotti","year":"2021","journal-title":"Cell"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e30124","DOI":"10.1097\/MD.0000000000030124","article-title":"Prediction of lower extremity strength by nerve conduction study in cauda equina syndrome","volume":"101","author":"Han","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1326-9-24","article-title":"Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant tdp-43 (a315t) mice","volume":"9","author":"Herdewyn","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"643254","DOI":"10.3389\/fphar.2021.643254","article-title":"Neurodegenerative disease and the nlrp3 inflammasome","volume":"12","author":"Holbrook","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.3233\/JAD-215511","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of hgf\/met, fosgonimeton, in healthy volunteers and subjects with Alzheimer's disease: randomized, placebo-controlled, double-blind, phase i clinical trial","volume":"86","author":"Hua","year":"2022","journal-title":"J. Alzheimers Dis."},{"key":"ref35","first-page":"S320","article-title":"Amyotrophic lateral sclerosis: disease state overview","volume":"24","author":"Hulisz","year":"2018","journal-title":"Am. J. Manag. Care"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1097\/nen.0b013e318159886b","article-title":"Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model","volume":"66","author":"Ishigaki","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s12035-018-1218-2","article-title":"Pathological modification of tdp-43 in amyotrophic lateral sclerosis with SOD1 mutations","volume":"56","author":"Jeon","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s12276-020-00513-7","article-title":"The role of tdp-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies","volume":"52","author":"Jo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13311-022-01325-5","article-title":"Fosgonimeton, a novel positive modulator of the hgf\/met system, promotes neurotrophic and procognitive effects in models of dementia","volume":"20","author":"Johnston","year":"2023","journal-title":"Neurotherapeutics"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/ng.132","article-title":"Tardbp mutations in individuals with sporadic and familial amyotrophic lateral sclerosis","volume":"40","author":"Kabashi","year":"2008","journal-title":"Nat. Genet."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","article-title":"Amyotrophic lateral sclerosis","volume":"377","author":"Kiernan","year":"2011","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41582-020-00434-z","article-title":"Improving clinical trial outcomes in amyotrophic lateral sclerosis","volume":"17","author":"Kiernan","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"8316","DOI":"10.1038\/s41598-018-26704-x","article-title":"Hepatocyte growth factor (hgf) promotes peripheral nerve regeneration by activating repair schwann cells","volume":"8","author":"Ko","year":"2018","journal-title":"Sci. Rep."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40478-019-0737-z","article-title":"Intrathecal delivery of recombinant aav1 encoding hepatocyte growth factor improves motor functions and protects neuromuscular system in the nerve crush and sod1-g93a transgenic mouse models","volume":"7","author":"Lee","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40035-022-00331-z","article-title":"Tdp-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis","volume":"11","author":"L\u00e9pine","year":"2022","journal-title":"Transl Neurodegener"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fnins.2020.00575","article-title":"Peripheral and central nervous system immune response crosstalk in amyotrophic lateral sclerosis","volume":"14","author":"Liu","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3389\/fimmu.2017.01005","article-title":"Role of neuroinflammation in amyotrophic lateral sclerosis: cellular mechanisms and therapeutic implications","volume":"8","author":"Liu","year":"2017","journal-title":"Front. Immunol."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fnins.2020.00579","article-title":"Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value","volume":"14","author":"Loeffler","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1212\/WNL.0000000000001642","article-title":"Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis","volume":"84","author":"Lu","year":"2015","journal-title":"Neurology"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1083\/jcb.85.3.890","article-title":"Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue","volume":"85","author":"McCarthy","year":"1980","journal-title":"J. Cell Biol."},{"key":"ref51","first-page":"305","article-title":"Tocilizumab attenuates inflammation in als patients through inhibition of il6 receptor signaling","volume":"1","author":"Mizwicki","year":"2012","journal-title":"Am. J. Neurodegener. Dis."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1212\/01.wnl.0000188907.97339.76","article-title":"Elevated il-6 and tnf-alpha levels in patients with ALS: inflammation or hypoxia?","volume":"65","author":"Moreau","year":"2005","journal-title":"Neurology"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3390\/ijms22052523","article-title":"Inflammasome in ALS skeletal muscle: Nlrp3 as a potential biomarker","volume":"22","author":"Moreno-Garc\u00eda","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00401-008-0477-9","article-title":"Phosphorylation of s409\/410 of tdp-43 is a consistent feature in all sporadic and familial forms of tdp-43 proteinopathies","volume":"117","author":"Neumann","year":"2009","journal-title":"Acta Neuropathol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/antiox9090901","article-title":"Oxidative stress, neuroinflammation and mitochondria in the pathophysiology of amyotrophic lateral sclerosis","volume":"9","author":"Obrador","year":"2020","journal-title":"Antioxidants"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-510X(01)00514-7","article-title":"Increased interleukin-6 of skin and serum in amyotrophic lateral sclerosis","volume":"187","author":"Ono","year":"2001","journal-title":"J. Neurol. Sci."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1021\/acschemneuro.9b00026","article-title":"Tdp-43: a key therapeutic target beyond amyotrophic lateral sclerosis","volume":"10","author":"Palomo","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3389\/fneur.2018.01167","article-title":"Diagnostic and prognostic performance of neurofilaments in als","volume":"9","author":"Poesen","year":"2018","journal-title":"Front. Neurol."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnmol.2019.00025","article-title":"Molecular mechanisms of tdp-43 misfolding and pathology in amyotrophic lateral sclerosis","volume":"12","author":"Prasad","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"ref60","volume-title":"Electrodiagnostic evaluation of motor neuron disease","author":"Ramroop","year":"2022"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/brain\/awab285","article-title":"Phosphorylated tdp-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis","volume":"145","author":"Riva","year":"2022","journal-title":"Brain"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-319-55769-4_6","article-title":"Eaat2 and the molecular signature of amyotrophic lateral sclerosis","volume":"16","author":"Rosenblum","year":"2017","journal-title":"Adv Neurobiol."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ana.410380114","article-title":"Selective loss of glial glutamate transporter glt-1 in amyotrophic lateral sclerosis","volume":"38","author":"Rothstein","year":"1995","journal-title":"Ann. Neurol."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s13311-015-0338-x","article-title":"Tdp-43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets","volume":"12","author":"Scotter","year":"2015","journal-title":"Neurotherapeutics"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/S0022-510X(97)00228-1","article-title":"Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases","volume":"154","author":"Sekizawa","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/acn3.795","article-title":"Blood neurofilament light as a potential endpoint in phase 2 studies in ms","volume":"6","author":"Sormani","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13024-022-00515-1","article-title":"Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis","volume":"17","author":"Staats","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"ref68","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/21678421.2016.1259334","article-title":"Open label study to assess the safety of vm202 in subjects with amyotrophic lateral sclerosis","volume":"18","author":"Sufit","year":"2017","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"579094","DOI":"10.3389\/fneur.2020.579094","article-title":"Correlational analysis of ALS progression and serum nfl measured by simoa assay in Chinese patients","volume":"11","author":"Sugimoto","year":"2020","journal-title":"Front. Neurol."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13024-020-00397-1","article-title":"The role of tdp-43 mislocalization in amyotrophic lateral sclerosis","volume":"15","author":"Suk","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","article-title":"The epidemiology of amyotrophic lateral sclerosis","volume":"138","author":"Talbott","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"ref72","volume-title":"Development of stable, orally available, small-molecule positive modulators of hgf\/met signaling for the treatment of cognitive impairment","author":"Taylor","year":"2022"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1111\/j.1468-1331.2012.03777.x","article-title":"Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression","volume":"19","author":"Tortelli","year":"2012","journal-title":"Eur. J. Neurol."},{"key":"ref74","doi-asserted-by":"publisher","first-page":"552295","DOI":"10.3389\/fneur.2020.552295","article-title":"Plasma inflammatory cytokines are elevated in ALS","volume":"11","author":"Tortelli","year":"2020","journal-title":"Front. Neurol."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"8542","DOI":"10.3390\/ijms21228542","article-title":"A novel hgf\/sf receptor (met) agonist transiently delays the disease progression in an amyotrophic lateral sclerosis mouse model by promoting neuronal survival and dampening the immune dysregulation","volume":"21","author":"Vallarola","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.3390\/ijms20112818","article-title":"Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques","volume":"20","author":"van den Bos","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.tins.2021.04.008","article-title":"Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis","volume":"44","author":"Van Harten","year":"2021","journal-title":"Trends Neurosci."},{"key":"ref78","doi-asserted-by":"crossref","DOI":"10.36255\/exonpublications.amyotrophiclateralsclerosis.astrocytes.2021","article-title":"Astrocytes in amyotrophic lateral sclerosis","volume-title":"Amyotrophic lateral sclerosis","author":"Vaz","year":"2021"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp-2018-318704","article-title":"Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis","volume":"90","author":"Verde","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1007\/s12035-021-02658-6","article-title":"Neuromuscular junction dysfunction in amyotrophic lateral sclerosis","volume":"59","author":"Verma","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.nbd.2004.03.001","article-title":"Igf-i prevents glutamate-induced motor neuron programmed cell death","volume":"16","author":"Vincent","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/jcph.1355","article-title":"Safety, tolerability, and pharmacodynamics of intrathecal injection of recombinant human hgf (kp-100) in subjects with amyotrophic lateral sclerosis: a phase i trial","volume":"59","author":"Warita","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1136\/practneurol-2011-000126","article-title":"Snaps, cmaps and f-waves: nerve conduction studies for the uninitiated","volume":"12","author":"Whittaker","year":"2012","journal-title":"Pract. Neurol."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1212\/NXI.0000000000000631","article-title":"Il6 receptor(358) ALA variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis","volume":"6","author":"Wosiski-Kuhn","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1073\/pnas.98.1.247","article-title":"Anti-apoptotic signaling by hepatocyte growth factor\/met via the phosphatidylinositol 3-kinase\/akt and mitogen-activated protein kinase pathways","volume":"98","author":"Xiao","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.neures.2017.09.011","article-title":"The multi-dimensional roles of astrocytes in ALS","volume":"126","author":"Yamanaka","year":"2018","journal-title":"Neurosci. Res."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"e0255710","DOI":"10.1371\/journal.pone.0255710","article-title":"Low-level overexpression of wild type tdp-43 causes late-onset, progressive neurodegeneration and paralysis in mice","volume":"17","author":"Yang","year":"2022","journal-title":"PLoS One"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1046\/j.0022-3042.2001.00683.x","article-title":"Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis","volume":"80","author":"Yoshihara","year":"2002","journal-title":"J. Neurochem."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1348157\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T05:10:12Z","timestamp":1707369012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2024.1348157\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,8]]},"references-count":88,"alternative-id":["10.3389\/fnins.2024.1348157"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2024.1348157","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,8]]},"article-number":"1348157"}}